Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Fortunato, Pina ^a   Pillozzi, Serena ^b   Tamburini, Angela ^a   Pollazzi, Liliana ^c   Franchi, Alessandro ^b   La Torre, Agostino ^b   Arcangeli, Annarosa ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Orthoptist Ophthalmology Assistant   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IFOSFAMIDE; MESNA; POTASSIUM CHANNEL HERG1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VINCRISTINE; VOLTAGE GATED POTASSIUM CHANNEL; ANGIOGENESIS INHIBITOR; KCNH1 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG; VEGFA PROTEIN, HUMAN;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; CHILD; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CRYOTHERAPY; ENUCLEATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; INTRAOCULAR HYPERTENSION; LEUKOKORIA; LOW LEVEL LASER THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PROTEIN EXPRESSION; RETINA DETACHMENT; RETINOBLASTOMA; TREATMENT RESPONSE; UPREGULATION; VITREOUS BODY; CANCER INVASION; DRUG RESISTANCE; FOLLOW UP; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RETINA TUMOR;

ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RETINAL NEOPLASMS; RETINOBLASTOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956828137     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-504     Document Type: Article

References (28)

1. Murphree AL, Munier FL. Retinoblastoma. Retina 1994, 571-626. Mosby, St. Louis, Ryan SJ, 2.
2. Shields CL, Shields JA. Recent development in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 1999, 36:8-18.
3. Ferris FL, Chew EY. A new era for treatment of retinoblastoma. Arch Ophthalmol 1996, 114:1412.
4. Shields JA, Shields CL. Management and prognosis of retinoblastoma. Intraocular tumors 1992, 377-391. WB Saunders, Philadelphia.
5. Shields C, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol 1993, 77:544-548. 10.1136/bjo.77.9.544, 513947, 8218048.
6. Shields C. Optic nerve invasion of retinoblastoma: metastatic potential and clinical risk factor. Cancer 1994, 73:692-698. 10.1002/1097-0142(19940201)73:3<692::AID-CNCR2820730331>3.0.CO;2-8, 8299091.
7. Chan HSL, Thorner PS, Haddad G, Gallie B. Effect of chemotherapy on intraocular retinoblastoma. Int J Pediatr Hematol Oncol 1995, 2:269-281.
8. Shields CL, Honavar SG, Meadows AT. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002, 133:657-664. 10.1016/S0002-9394(02)01348-X, 11992863.
9. Friedman DL, Himelstein B, Shields CL. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000, 18:12-17.
10. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol 2000, 118:577-578.
11. Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Trans Am Ophthalmol Soc 2004, 102:35-44. 1280085, 15747743.
12. Schweigerer L. Anti-angiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 1995, 73:497-508. 10.1007/BF00198901, 8581511.
13. Rössler J, Dietrich T, Pavlakovic H. Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol 2004, 164:391-394. 1602251, 14742245.
14. Areán C, Orellana ME, Abourbih D, Abreu C, Pifano I, Burnier MN. Expression of vascular endothelial growth factor in retinoblastoma. Arch Ophthalmol 2010, 128(2):223-229. 10.1001/archophthalmol.2009.386, 20142546.
15. Jockovich ME, Piña Y, Alegret A, Cebulla C, Feuer W, Murray TG. Heterogeneous tumor vasculature in retinoblastoma: implications for vessel targeting therapy. Retina 2008, 28:S81-86. 10.1097/IAE.0b013e318150d6f0, 18317352.
16. Piña Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG. Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci 2009, 50(3):1020-1024. 10.1167/iovs.08-2654, 18952925.
17. Marback EF, Arias VE, Paranhos A, Soares FA, Murphree AL, Erwenne CM. Tumor angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol 2003, 87(10):1224-1228. 10.1136/bjo.87.10.1224, 1920792, 14507753.
18. Pillozzi S, Brizzi MF, Balzi M, Crociani O, Cherubini A, Guasti L, Bartolozzi B, Becchetti A, Wanke E, Bernabei PA, Olivotto M, Pegoraro L, Arcangeli A. HERG K+ channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 2002, 16:1791-1798. 10.1038/sj.leu.2402572, 12200695.
19. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, Boddi V, Pegoraro L, Becchetti A, Arcangeli A. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 2007, 110:1238-1250. 10.1182/blood-2006-02-003772, 17420287.
20. Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, Bencini L, Calistri M, Messerini L, Scatizzi M, Moretti R, Wanke E, Olivotto M, Mugnai G, Arcangeli A. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 2004, 64:606-611. 10.1158/0008-5472.CAN-03-2360, 14744775.
21. Lee SH, Yoo KH, Sung KW, Kim JY, Cho EJ, Koo HH, Chung SE, Kang SW, Oh SY, Ham DI, Kim YD. Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplantation 2008, 42:385-391. 10.1038/bmt.2008.181, 18574441.
22. Sonmez K, Drenser KA, Capone A, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008, 115:1065-1070. 10.1016/j.ophtha.2007.08.050, 18031819.
23. Tatlipinar S, Söylemezoglu F, Kiratli H, Bilgiç S. Quantitative analysis of apoptosis in retinoblastoma. Clin Experiment Ophthalmol 2002, 30(2):131-135. 10.1046/j.1442-6404.2002.00500.x, 11886418.
24. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R. Retinoblastoma: review of current management. Oncologist 2007, 12:1237-1246. 10.1634/theoncologist.12-10-1237, 17962617.
25. Olver J, McCartney ACE, Kingston J, Hungerford J. Histological indicators of the prognosis for survival following enucleation for retinoblastoma. Tumors of the Eye. New York 1991, 59-67. Bornfeld N, Gragoudas ES, Höpping W, Lommatzsch PK.
26. Pavlakovic H, Havers W, Schweigerer L. Multiple angiogenesis stimulators in a single malignancy. Angiogenesis 2001, 4:259-262. 10.1023/A:1016045012466, 12197470.
27. Crociani O, Lastraioli E, Pillozzi S, Zanieri F, Fortunato A, Masi A, Fiore A, Wanke E, Arcangeli A. hERG1 channels regulate VEGF-A secretion and in vivo angiogenesis in gastrointestinal cancers. 2nd International Meeting Ion Channels and Cancer, Florence 2010,
28. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem 2009, 16:66-93. 10.2174/092986709787002835, 19149563.